# Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)

> **NCT01562301** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Anvirzel
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT01562301
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-06
- **Primary completion:** 2016-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-06-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562301, "Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)". Retrieved via MORVS 2026-11-19 from https://api.morvs.ai/clinical/NCT01562301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
